drugset / Trial / NCT00649168
Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study was to assess the single-dose relative bioavailability of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 5 mg bromocriptine mesylate capsules, following the administration of a 10 mg dose, under fed conditions.
Timeline
- Start
- 2007-04
- Primary completion
- 2007-06
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bromocriptine | Small molecule | 10 mg | — |
Indications
No indication recorded.